April 11, 2024 – Page 7 – Goldea Capital

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Written by Customer Service on April 11, 2024. Posted in Mergers And Acquisitions.

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Companies to host webcast today, April 11, 2024 at 8:30 a.m. EDT SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”) and Tenet Medicines, Inc. (“Tenet”), a development-stage private biotechnology company, today announced that the companies have entered into a definitive...

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Written by Customer Service on April 11, 2024. Posted in Mergers And Acquisitions.

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026 Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform Newly expanded pipeline incorporates three additional preclinical-stage programs from Clade’s αβ iT platform spanning across cancer and autoimmune diseases PHILADELPHIA, April 11, 2024 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent...

The Lovesac Company Reports Fourth Quarter and Fiscal 2024 Financial Results

Written by Customer Service on April 11, 2024. Posted in Earnings Releases And Operating Results.

Fourth Quarter Net Sales Growth of 5.0%Fiscal Year Net Sales Growth of 7.5% STAMFORD, Conn., April 11, 2024 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World’s Most Adaptable Couch, today announced financial results for the fourth quarter and fiscal 2024, which ended February 4, 2024. Note: Lovesac’s fourth quarter and fiscal 2024 results contain an additional, non-comparable week, or the “53rd week”, when compared to the fourth quarter and full year results for the respective 52- and 13-week periods ended January 29, 2023 (“fiscal 2023”), and full year guidance for the 52-week fiscal year ending February 2, 2025 (“fiscal 2025”). Unless stated otherwise, financial metrics discussed in this release, such as net...

Meriaura Group Oyj: Notice to the Annual General Meeting of Meriaura Group Plc.

Written by Customer Service on April 11, 2024. Posted in Public Companies.

Meriaura Group Plc Company Release 11 April 2024 at 13.30 (CET) Notice to the Annual General Meeting of Meriaura Group Plc. Notice is given to the shareholders of Meriaura Group Plc. to the Annual General Meeting to be held on Friday, 3 May 2024 at 9.30 (EET) at Scandic Simonkenttä’s Mansku meeting room, address Simonkatu 9, Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 9.00 (EET). A. Matters on the agenda of the General Meeting At the General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording the attendance at the meeting and...

Crown Castle Highlights Actions Underway to Create Stronger and More Valuable Company

Written by Customer Service on April 11, 2024. Posted in Public Companies.

Files Definitive Proxy Materials and Mails Letter to Shareholders Urges Shareholders to Vote “FOR” Only Crown Castle’s 13 Qualified and Experienced Nominees on the WHITE Proxy Card Ted Miller is Seeking De Facto Control of the Company by Installing Himself as Executive Chair and Appointing His Family and Friends to the Board HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) — Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming 2024 Annual Meeting of Shareholders (the “2024 Annual Meeting”) scheduled for May 22, 2024. Shareholders of record as of the close of business on March 28, 2024 are entitled to vote at the 2024 Annual Meeting. In connection with the filing of the definitive proxy...

Rail Vision Received $1 Million Order out of a Contract Valued at Up to $5 Million with Leading US-Based Rail and Leasing Services Company

Written by Customer Service on April 11, 2024. Posted in Public Companies.

Ra’anana, Israel, April 11, 2024 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (the “Company”), a technology company at the forefront of revolutionizing railway safety and the data-related market, announced today that it has received an initial purchase order amounting to approximately $1 million as part of a contract valued at up to $5 million with a leading US-based rail and leasing services company that the Company announced on January 17, 2024. The order is for the purchase of Rail Vision’s AI-based ShuntingYard products, which are expected to be installed during the third quarter of this year. “We’re delighted with the successful execution of our contract with this esteemed customer, marking the receipt of our initial order from it. Since the start of 2024, we’ve been expanding our presence in the US, achieving...

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Written by Customer Service on April 11, 2024. Posted in Public Companies.

Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications. Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufacturing, process development, plant operations and global supply chain management. “We are honored to have Carole join Codexis as the newest member of our Strategic Advisory Board,” said Stefan...

LNG Energy Group Announces Successful ISO Recertifications

Written by Customer Service on April 11, 2024. Posted in Public Companies.

TORONTO, April 11, 2024 (GLOBE NEWSWIRE) — LNG Energy Group Corp. (TSXV: LNGE) (TSXV: LNGE.WT) (OTCQB: LNGNF) (FRA: E26) (the “Company” or “LNG Energy Group”) is pleased to announce that its wholly owned subsidiary, Lewis Energy Colombia, Inc. (“LEC”), has successfully completed the following ISO recertifications, after an audit performed by Bureau Veritas: 9001:2015 – Quality Management System (QMS): this certification recognizes LEC for its successful implementation and continual improvement of its QMS. 14001:2015 – Environmental Management Systems (EMS): this certification recognizes LEC’s commitment to take proactive measures to minimize its environmental footprint, comply with relevant legal requirements and achieve their environmental objects. 45001:2018 – Occupational Health and Safety (OH&S) Management System: this...

ForFarmers N.V.: Resolutions General Meeting of Shareholders ForFarmers N.V.

Written by Customer Service on April 11, 2024. Posted in Public Companies.

Press release Lochem, 11 April 2024 Resolutions General Meeting of Shareholders ForFarmers N.V.During the General Meeting of Shareholders of ForFarmers N.V. (hereinafter referred to as the ‘General Meeting’ and ‘ForFarmers’ respectively), held today, the shareholders adopted the financial statements for the 2023 financial year and also approved the dividend proposal for the said financial year. The dividend of € 0,15 per ordinary share will be paid to ForFarmers’ shareholders entirely in cash, after deducting 15% dividend withholding tax. The ex-dividend date is 15 April 2024 and and the dividend will be paid on April 24, 2024. Other resolutions An advisory vote was cast in favour of the 2023 remuneration report (for 97,2 %; against 2,8%). Discharge was granted to each member of the Executive...

STERIS to Sell Dental Segment to an affiliate of Peak Rock Capital

Written by Customer Service on April 11, 2024. Posted in Public Companies.

Transaction expected to close in STERIS’s first quarter of fiscal 2025 Divestiture allows STERIS to focus on Customers within core markets Proceeds primarily to be used to repay debt DUBLIN, IRELAND, April 11, 2024 (GLOBE NEWSWIRE) — ) – STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has entered into a definitive agreement to divest its Dental segment to Peak Rock Capital, a leading middle-market private investment firm, for $787.5 million (the “Transaction”). The Transaction is structured as an equity sale. The Transaction terms also include the opportunity for STERIS to receive an additional earnout of up to $12.5 million, subject to the achievement of certain revenue targets of the Dental segment in fiscal 2025. The Dental segment reported revenue of $407 million and contributed segment...

Day: April 11, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice